What type of study is this?

This is a Meta-Analysis study (also classified as: Systematic Review).

December 8, 2025Blood

Prophylactic immunoglobulin supplementation for infection prevention in multiple myeloma: An updated systematic review and meta-analysis

View Full Paper

Ask AI

Bookmark

Authors

AMAkihiro MiyashitaUniversity of Hawaiʻi at Mānoa KTKensuke TakaokaThe University of Texas MD Anderson Cancer Center

Discussion

Member takes

Implication

Systematic review and meta-analysis reveal prophylactic immunoglobulin reduces severe infections in multiple myeloma patients, suggesting benefits in infection prevention strategies.

Key Points

Prophylactic immunoglobulin is associated with a lower incidence of severe infections in patients with multiple myeloma.
A total of 18 studies contributed, showing an odds ratio of 0.22 for severe infections with immunoglobulin use.
Analysis included randomized controlled trials and observational studies to evaluate immunoglobulin efficacy.
Further research needed to explore immunoglobulin impact on infection prevention in patients receiving CAR-T therapy.

Cite This Study

Miyashita et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e4f2 https://doi.org/10.1182/blood-2025-7531

View Full Paper

Ask AI

Bookmark

Implication

Systematic review and meta-analysis reveal prophylactic immunoglobulin reduces severe infections in multiple myeloma patients, suggesting benefits in infection prevention strategies.

Prophylactic immunoglobulin supplementation for infection prevention in multiple myeloma: An updated systematic review and meta-analysis

Discussion

Member takes

Implication

Key Points

Cite This Study

Prophylactic immunoglobulin supplementation for infection prevention in multiple myeloma: An updated systematic review and meta-analysis

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider